Physician profile
Christopher M Lodowsky
NPI 1427172758
$6,239.84
in general payments reported to CMS, 2019-2025
39 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $389 · 2021: $931 · 2022: $518 · 2023: $666 · 2024: $623 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Consulting Fee: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.58 |
| Consulting Fee | $1,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,277.06 | 2025 | |
| Astellas Pharma US INC | $691.44 | 2019-2025 | Xtandi |
| Myovant Sciences INC. | $485.65 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $467.27 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $401.83 | 2019-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $340.08 | 2019-2025 | Ams 700 |
| Ferring Pharmaceuticals INC. | $324.40 | 2019-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $308.26 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $216.31 | 2023-2025 | |
| Urogen Pharma, INC. | $198.09 | 2020-2025 | |
| Coloplast Corp | $147.81 | 2023 | Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $137.49 | 2021-2025 | |
| Amgen INC. | $110.77 | 2019-2021 | |
| Caldera Medical, INC | $101.35 | 2021 | |
| Olympus America INC. | $95.94 | 2020-2025 | Itind System |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $94.64 | 2019-2021 | |
| Axonics, INC. | $74.16 | 2021-2024 | Axonics |
| Travere Therapeutics, INC. | $71.73 | 2019-2021 | |
| Blue Earth Diagnostics | $62.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $62.20 | 2021-2022 | |
| Antares Pharma, INC. | $59.83 | 2020-2021 | |
| Pfizer INC. | $58.82 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $52.89 | 2019-2021 | |
| Immunitybio, INC. | $48.24 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $41.08 | 2023-2024 | Welireg, Keytruda, Lynparza |
| Endo USA, INC. | $40.10 | 2024 | Xiaflex |
| 180 Medical, INC. | $39.41 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $28.48 | 2022 | |
| Fresenius Kabi USA, LLC | $25.93 | 2025 | |
| Genzyme Corporation | $24.41 | 2021 | |
| Verity Pharmaceuticals INC. | $20.22 | 2022 | |
| Laborie Medical Technologies Corp. | $19.59 | 2024 | Goby |
| Teleflex LLC | $18.80 | 2021 | |
| Tolmar, INC. | $17.96 | 2025 | Jatenzo, Eligard |
| Allergan, INC. | $17.19 | 2021 | |
| Profound Medical Corp. | $15.99 | 2025 | Tulsa-Pro |
| Emd Serono, INC. | $15.67 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.03 | 2019 | |
| Neotract INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lodowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.